Psyence Biomedical Ltd. (PBM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Psyence Biomedical Ltd. (PBM) closed at USD 4.32 on 2026-10-15, a change of -96.6 % over the past year, with a market capitalization of USD 16.1M.

Psyence Biomedical Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Psyence Biomedical Ltd. key figures

Previous close

USD 4.32 (2026-10-15)

1-year change

-96.6 %

Market cap

USD 16.1M

Enterprise value

USD 8.65M

P/E ratio (trailing)

-0.34

P/E ratio (forward)

n/a

EPS (trailing)

-12.56

EPS (forward)

n/a

PEG ratio

n/a

Price to book

0.57

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.31

Employees

12

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Psyence Biomedical Ltd.

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Psyence Biomedical Ltd. and compare it with other stocks.